Eli Lilly and Company (BIT:1LLY)

Market Cap	825.66B
Revenue (ttm)	50.64B
Net Income (ttm)	15.69B
Shares Out	n/a
EPS (ttm)	17.42
PE Ratio	52.61
Forward PE	34.01
Dividend	5.36 (0.60%)
Ex-Dividend Date	Nov 13, 2025

Volume	632
Average Volume	436
Open	887.40
Previous Close	887.40
Day's Range	884.70 - 916.20
52-Week Range	535.20 - 972.00
Beta	n/a
RSI	52.90
Earnings Date	Feb 4, 2026

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja...

• Industry: Pharmaceutical Preparations
• Founded: 1876
• Employees: 47,000
• Stock Exchange: Borsa Italiana
• Ticker Symbol: 1LLY

Financial Performance

In 2024, Eli Lilly and Company's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.

Financial numbers in USD